January 15, 2026
Azomedicine Announces Appointment of Dr. James Patterson as SVP and Head of Research
Boston, MA – Azomedicine, a leading discovery-stage biotech company dedicated to developing next-generation treatments for patients with metabolic diseases, today proudly announces the appointment of James Patterson, PhD as Senior Vice President and Head of Research and Translational Science. Dr. Patterson brings a wealth of cross-functional experience as a research leader, translational medicine expert and company builder and has a proven track record of success in building and translating innovative therapeutic programs.
"We are thrilled to welcome James to the executive leadership team of Azomedicine," said Marcus Chen, CEO, President and Co-Founder of the company. "James brings deep expertise in mitochondrial biology and metabolic disease and has led complex drug development programs at the intersection of research, translation and clinical development."
November 8, 2025
Azomedicine Receives $2.5M Grant from the Harrison Foundation for Diabetes Research
Boston, MA – Azomedicine today announced it has been awarded a $2.5 million research grant from the Harrison Foundation to advance its MPC1 agonist program for the treatment of type 2 diabetes. The grant will support preclinical development and IND-enabling studies.
"We appreciate the generous support from the Harrison Foundation, which underlines the importance of mitochondrial ion channels as drug targets for diabetes," said Dr. Marcus Chen, chief executive officer of Azomedicine. "This grant and our relationship with the Harrison Foundation will bring us closer to the diabetes research community and expedite our overall translational research effort. Azomedicine plans to use the grant to investigate the therapeutic potential of its MPC1 modulators in preclinical models of diabetes, particularly focusing on discovery and development of target engagement and pharmacodynamic biomarkers."
September 22, 2025
Azomedicine Appoints Dr. Robert Sullivan to Board of Directors
Boston, MA – Azomedicine, a leading discovery-stage biotech company dedicated to developing next-generation treatments for patients with metabolic diseases, today proudly announces the appointment of Robert Sullivan, PhD to its board of directors. Dr. Sullivan brings a wealth of experience as a distinguished business leader, entrepreneur and mentor, with a proven track record of guiding biotechnology companies towards maximizing program value and realizing their full potential.
"We are thrilled to welcome Robert to the Azomedicine board of directors as we advance our pipeline into clinical studies next year," said Marcus Chen, CEO & President, Co-Founder of Azomedicine. "Robert's extensive industry expertise and strategic guidance will be invaluable to Azomedicine as we bolster our team and navigate key milestones in 2025 and beyond."
June 30, 2025
Azomedicine Closes $45 Million Series A Financing
Boston, MA – Azomedicine today announced the closing of a $45 million Series A financing round led by NextGen Bioventures and Pacific Health Capital, with participation from Atlas Medical Ventures and existing investors. The funding will support advancement of Azomedicine's lead programs through IND-enabling studies and expansion of its mitochondrial ion channel platform.
"This financing validates our innovative approach to treating metabolic diseases through modulation of mitochondrial ion channels," said Dr. Marcus Chen. "With this capital, we can accelerate our lead programs and expand our pipeline to address multiple metabolic disorders with high unmet medical need."
March 15, 2025
Azomedicine Founded to Develop Mitochondrial Ion Channel Modulators
Boston, MA – Azomedicine launched today with seed funding to develop a novel class of therapeutics targeting mitochondrial ion channels for metabolic diseases. Founded by leading experts in mitochondrial biology and drug discovery, the company aims to address critical gaps in the treatment of diabetes, obesity, and rare metabolic disorders.
The company's founding is based on breakthrough research demonstrating the central role of mitochondrial ion channels in metabolic homeostasis and the potential for small molecule modulators to restore metabolic function in disease states.